Breaking News on Global Pharmaceutical Technology & Manufacturing

News in brief

Dainippon to buy Sepracor for $2.6bn

03-Sep-2009

Related topics: Regulatory & Safety, Globalisation, Mergers and acquisitions

Japanese drugmaker Dainippon Sumitomo Pharma (DSP) has entered into a definitive agreement to acquire US pharmaceutical group Sepracor for $2.6bn (€1.8bn).

In a statement earlier today DSP said that the deal fits with its strategy to “strengthen [its] business foundation as a first step in becoming a global corporation,” adding that the move will expand its US sales and marketing capability.

DSP’s efforts to bolster its US presence are timely given that it is preparing for the global launch of its new antipsychotic drug Lurasidone.

Company president Masayo Tada explained that: “Sepracor will become a centre of excellence for DSP in the US and will make a significant contribution to DSP.”

Copyright - Unless otherwise stated all contents of this web site are © 2012 - William Reed Business Media SAS - All Rights Reserved - For permission to reproduce any contents of this web site, please email our Syndication department copyright@wrbm.com - Full details for the use of materials on this site can be found in the Terms & Conditions

© 2012 - William Reed Business Media SAS - All rights reserved.